Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncolytics Biotech Inc.

Latest From Oncolytics Biotech Inc.

AZ Targets Viral Oncolytics With Transgene Development Deal

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.

Research & Development Deals

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.

M & A Deals

Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates

In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.

Deals Intellectual Property

Oncolytics After 2017 Refresh: New CEO Makes New Year Resolutions

2018 will be a year of change for Calgary, Canada-based Oncolytics Biotech, according to its CEO Dr. Matt Coffey. After switching gears to focus on metastatic breast cancer as the lead indication for its oncolytic virus-based drug candidate Reolysin, the biotech is ready to enter Phase III and step-up its clinical and commercial activities.

Business Strategies Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Oncolytics Biotech Inc.
  • Senior Management
  • Matt Coffey, PhD, Pres. & CEO
    Kirk Look, CFO
    Andrew de Guttadauro, Global Head, Bus. Dev.
    Rita Laeufle, MD, CMO
  • Contact Info
  • Oncolytics Biotech Inc.
    Phone: (403) 670-7377
    210-1167 Kensington Crescent NW
    Calgary, T2N 1X7